Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation & Amortization (CF)Free Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Atea Pharmaceuticals (AVIR) Cash from Financing Activities (2020 - 2022)

Atea Pharmaceuticals has reported Cash from Financing Activities over the past 3 years, most recently at $147000.0 for Q3 2022.

  • Quarterly results put Cash from Financing Activities at $147000.0 for Q3 2022, down 81.51% from a year ago — trailing twelve months through Dec 2022 was $370000.0 (down 74.74% YoY), and the annual figure for FY2025 was -$25.7 million, down 9742.32%.
  • Cash from Financing Activities for Q3 2022 was $147000.0 at Atea Pharmaceuticals, down from $223000.0 in the prior quarter.
  • Over the last five years, Cash from Financing Activities for AVIR hit a ceiling of $426.2 million in Q4 2020 and a floor of -$913000.0 in Q3 2020.
  • Median Cash from Financing Activities over the past 3 years was $185000.0 (2022), compared with a mean of $53.4 million.
  • Peak annual rise in Cash from Financing Activities hit 7950.0% in 2021, while the deepest fall reached 99.97% in 2021.
  • Atea Pharmaceuticals' Cash from Financing Activities stood at $426.2 million in 2020, then crashed by 99.97% to $142000.0 in 2021, then grew by 3.52% to $147000.0 in 2022.
  • The last three reported values for Cash from Financing Activities were $147000.0 (Q3 2022), $223000.0 (Q1 2022), and $142000.0 (Q4 2021) per Business Quant data.